Ramelteon, the active ingredient in Rozerem, is not currently available as a generic in the United States. The drug's patent protection is still in effect, preventing generic manufacturers from entering the market.
When Can Generic Ramelteon Be Available?
The patent for ramelteon is set to expire in 2025 [1]. This date marks the earliest point when generic versions of Rozerem could become available, provided no further patent extensions or exclusivities are granted.
What Happens When Ramelteon Goes Generic?
Once ramelteon becomes available as a generic, it is expected that multiple manufacturers will release their own versions of the drug. This typically leads to a significant decrease in the price of the medication compared to the brand-name version, Rozerem [2]. Patients and insurance providers can then access a more affordable treatment option for insomnia.
How Does Ramelteon Work?
Ramelteon is a melatonin receptor agonist. It selectively binds to MT1 and MT2 receptors in the suprachiasmatic nucleus of the brain, which is involved in regulating the sleep-wake cycle [3]. By mimicking the effects of melatonin, ramelteon helps to signal to the body that it is time to sleep.
Who Makes Rozerem Now?
Rozerem is manufactured by Takeda Pharmaceuticals [4].
What are the Potential Risks if Generic Availability is Delayed?
If the generic availability of ramelteon is delayed beyond 2025 due to patent litigation or other regulatory hurdles, patients will continue to face the higher costs associated with the brand-name drug, Rozerem [1][2]. This can impact treatment accessibility and affordability for individuals managing insomnia.
What Are the Alternatives to Ramelteon?
For individuals with insomnia, various treatment options exist besides ramelteon. These include other prescription medications, such as benzodiazepines, non-benzodiazepine hypnotics (like zolpidem or eszopiclone), and orexin receptor antagonists. Behavioral therapies, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), are also widely recommended as a first-line treatment [5].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.rxlist.com/rozerem-drug.htm
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635443/
[4] https://www. Drugs.com/rozerem.html
[5] https://www.sleepfoundation.org/insomnia